Developer docs
API playgroundTry for free, no card

Search company profiles

Eye2Gene

Full company profile

uuid004e9gg

Namestring
Eye2Gene
Legal namestring
Eye2Gene Ltd
Websiteurl
eye2gene.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Eye2Gene is an AI-powered precision ophthalmology platform that combines advanced retinal imaging analysis with genomic insights to accelerate diagnosis of inherited retinal diseases (IRDs). Created as a spinout from UCL and registered as Eye2Gene Ltd in England and Wales, the company serves ophthalmologists, retinal specialists, and medical geneticists seeking diagnostic certainty; pharmaceutical companies pursuing IRD gene therapies and clinical trial enrollment; and patients affected by the 270+ genes associated with IRDs. The platform analyses routine retinal imaging (OCT, FAF, IR) using proprietary machine learning algorithms to surface imaging biomarkers and ranked candidate gene lists, integrating with genetic sequencing data to identify causative mutations and shorten diagnostic timelines from years to weeks.

The core Eye2Gene Platform bundles AI-powered imaging analysis, genomics integration, genetic prioritisation, and quantitative biomarker capabilities, supported by a Secure Data Portal featuring AES-256 encryption, role-based access controls, and audit logging. Clinical credibility is anchored to validation on more than 3,000 genetically characterised IRD patients drawn from Moorfields Eye Hospital, the University of Oxford, and University Hospital Bonn, and to peer-reviewed publications in Nature Machine Intelligence (2025), the British Journal of Ophthalmology (2025), and Ophthalmology Science (2024, 2022). The product is classified as a Class IIa medical device under EU MDR 2017/745, is currently undergoing Notified Body conformity assessment for CE marking, with a parallel UKCA marking pathway, and is being developed under ISO 13485, ISO 14971, IEC 62304, and ISO 27001 frameworks.

Eye2Gene operates an enterprise go-to-market motion, distributing clinical decision support software through direct field sales to healthcare institutions and pharmaceutical companies on quote-based multi-year subscription contracts, with pricing not publicly disclosed. Marketing emphasis is on peer-reviewed research, conference presence (ISS 2025, Flower AI Summit 2025), and academic partnerships rather than paid acquisition. The company is privately held and backed by a mix of venture (TwinPath), angel (Cambridge Angels), technology transfer (UCLB), and UK government and innovation funders (InnovateUK, NIHR, UCL CDI, KQ Labs, Adeline). The leadership team comprises four co-founders: CEO Nikolas Pontikos, PhD; CTO Ismail Moghul, PhD; Chief AI Officer William Woof, PhD; and CMO Professor Michel Michaelides.

Short descriptiontext

Eye2Gene is an AI-powered precision ophthalmology platform combining retinal imaging analysis with genomics to accelerate diagnosis of inherited retinal diseases for clinicians, pharmaceutical companies, and patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI ophthalmology platform, retinal imaging analysis, genomic decision support, inherited retinal disease diagnosis, clinical decision software
Industry3 codes
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Ophthalmic Goods3851
Product category
AI-Powered Precision Ophthalmology Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Platform subscription/usage
TypeSubscription Recurring
Description

Eye2Gene provides its AI-powered clinical decision support platform to healthcare institutions, pharma companies, and researchers. The platform is described as clinical decision support software not yet approved for clinical use. Revenue likely derives from platform licensing, subscription agreements, or usage-based pricing for institutional access, though specific commercial terms are not publicly disclosed.

eye2gene.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details1 tier
1Enterprise platform access (quote-based)
ModelSubscriptionBilling cadenceMulti-year contract
Notes

No public pricing tiers are available. Interested parties must request a demo or contact the company directly for pricing information. The platform is designed for institutional access by healthcare professionals, researchers, and pharmaceutical companies.

eye2gene.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Eye2Gene is an AI-powered precision ophthalmology platform that analyzes routine retinal imaging (OCT, FAF, IR) combined with genomic data to support clinicians in diagnosing inherited retinal diseases (IRDs). The platform generates ranked candidate gene lists and quantitative imaging biomarkers to streamline genetic testing workflows, accelerating diagnosis from years to weeks and supporting clinical trial patient identification for pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Diagnosis timeline reduced from years to weeks
+2 more records
Product overview1 text field

Eye2Gene is an AI-powered precision ophthalmology platform combining advanced imaging analysis with genomic insights. The core Eye2Gene Platform integrates AI-powered imaging analysis, genomics integration, genetic prioritisation, and quantitative biomarkers to accelerate inherited retinal disease diagnosis from years to weeks. The platform is supported by a Secure Data Portal enabling secure cloud infrastructure with encrypted data storage for research, clinical collaboration, and clinical trial readiness.

Product and service1 record
1Eye2Gene Platform
CategoryClinical decision support software
Description

AI-powered clinical decision support platform that analyses routine retinal imaging (OCT, FAF, IR) combined with genomic sequencing data to assist clinicians, researchers, and pharmaceutical companies in diagnosing inherited retinal diseases (IRDs). Generates ranked candidate gene lists and quantitative imaging biomarkers to accelerate diagnosis from years to weeks and supports clinical trial patient identification.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding institution and primary research collaborator. Eye2Gene was created as a spinout from UCL. Ongoing collaboration on AI-powered inherited retinal disease diagnosis research, validation studies, and technology development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading UK eye hospital and major clinical validation partner. Collaborating on clinical validation of Eye2Gene platform with genetically characterised IRD patient data. Key reference institution for clinical credibility.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical validation partner for Eye2Gene inherited retinal disease research. Collaborating on studies involving genetically characterised patients from Oxford.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

International clinical validation partner for Eye2Gene platform. Collaborating on inherited retinal disease studies with European patient populations.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

UK-based sight loss research charity. Collaborating on research into inherited retinal diseases and AI applications in ophthalmology.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

UK patient organisation for those affected by inherited retinal dystrophies. Collaborating on patient-focused research, webinars, and awareness activities.

7Stargardt Connected
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Patient advocacy group for Stargardt disease. Collaborating on patient engagement and community outreach.

eye2gene.com
8Moorfields Eye Charity
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Charitable arm of Moorfields Eye Hospital supporting research and innovation in eye health. Supporting Eye2Gene research and development activities.

eye2gene.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

NHS initiative supporting AI adoption in genomic medicine. Eye2Gene participates in NHS Clinical AI Interest Group activities for precision ophthalmology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Digital Diagnostics pioneered autonomous AI diagnostic software in ophthalmology (IDx-DR). Comparable as a regulatory-grade AI diagnostics platform targeting ophthalmic clinical workflows.

TypeDirect peer
Description

RetinAI builds AI tools (Discovery, iPredict) for OCT and fundus image analysis to support diagnosis and clinical trial recruitment in retinal disease. Directly comparable to Eye2Gene's imaging-based decision support and pharma patient-stratification focus.

TypeDirect peer
Description

Eyenuk develops FDA-cleared AI for retinal imaging (EyeArt for diabetic retinopathy). It is a direct peer to Eye2Gene in AI-based retinal disease detection, though focused on DR rather than IRDs.

TypeEmerging player
Description

Voxeleron provides OCT image analysis software and biomarkers for ophthalmic clinical research. Relevant peer in retinal image quantification that complements the imaging-analysis half of Eye2Gene's platform.

TypeEmerging player
Description

AEYE Health develops AI screening for diabetic retinopathy from retinal images, focused on primary care. Emerges as a peer in retinal AI diagnostics, overlapping with Eye2Gene's imaging-based triage/decision support value prop.

6Tempus AI
TypeOthers
Description

Tempus builds multimodal AI combining imaging, genomic, and clinical data to inform precision medicine, including in ophthalmology. Adjacent enabling peer representing the broader precision-medicine AI infrastructure Eye2Gene's imaging-genomics model resembles.

7Genomics England / NHS Genomic Medicine Service
TypeOthers
Description

UK national genomics initiatives in inherited disease diagnosis. Adjacent ecosystem participant and potential buyer/partner for Eye2Gene's genetic prioritisation technology in the NHS pathway.

TypeBroad incumbent
Description

DeepMind (Google Health) has published foundational AI work on OCT-based retinal disease detection. Broad incumbent peer representing the big-tech competitive threat in AI retinal diagnostics.

TypeBroad incumbent
Description

Heidelberg Engineering develops SPECTRALIS OCT and fundus imaging platforms widely used in retinal care. An incumbent imaging-device vendor whose hardware Eye2Gene's software analyses, and which itself markets image-analysis software for retinal disease.

10Carl Zeiss Meditec
TypeBroad incumbent
Description

Carl Zeiss Meditec is a major ophthalmology device vendor (Cirrus OCT, Humphrey field analyser) with growing clinical software offerings. Broad incumbent comparable as the wider ophthalmology imaging/diagnostics ecosystem Eye2Gene operates in.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eye2Gene

AI-Powered Precision Ophthalmology Softwareeye2gene.com

Eye2Gene is an AI-powered precision ophthalmology platform combining retinal imaging analysis with genomics to accelerate diagnosis of inherited retinal diseases for clinicians, pharmaceutical companies, and patients.

What Eye2Gene does

Eye2Gene is an AI-powered precision ophthalmology platform that combines advanced retinal imaging analysis with genomic insights to accelerate diagnosis of inherited retinal diseases (IRDs). Created as a spinout from UCL and registered as Eye2Gene Ltd in England and Wales, the company serves ophthalmologists, retinal specialists, and medical geneticists seeking diagnostic certainty; pharmaceutical companies pursuing IRD gene therapies and clinical trial enrollment; and patients affected by the 270+ genes associated with IRDs. The platform analyses routine retinal imaging (OCT, FAF, IR) using proprietary machine learning algorithms to surface imaging biomarkers and ranked candidate gene lists, integrating with genetic sequencing data to identify causative mutations and shorten diagnostic timelines from years to weeks.

The core Eye2Gene Platform bundles AI-powered imaging analysis, genomics integration, genetic prioritisation, and quantitative biomarker capabilities, supported by a Secure Data Portal featuring AES-256 encryption, role-based access controls, and audit logging. Clinical credibility is anchored to validation on more than 3,000 genetically characterised IRD patients drawn from Moorfields Eye Hospital, the University of Oxford, and University Hospital Bonn, and to peer-reviewed publications in Nature Machine Intelligence (2025), the British Journal of Ophthalmology (2025), and Ophthalmology Science (2024, 2022). The product is classified as a Class IIa medical device under EU MDR 2017/745, is currently undergoing Notified Body conformity assessment for CE marking, with a parallel UKCA marking pathway, and is being developed under ISO 13485, ISO 14971, IEC 62304, and ISO 27001 frameworks.

Eye2Gene operates an enterprise go-to-market motion, distributing clinical decision support software through direct field sales to healthcare institutions and pharmaceutical companies on quote-based multi-year subscription contracts, with pricing not publicly disclosed. Marketing emphasis is on peer-reviewed research, conference presence (ISS 2025, Flower AI Summit 2025), and academic partnerships rather than paid acquisition. The company is privately held and backed by a mix of venture (TwinPath), angel (Cambridge Angels), technology transfer (UCLB), and UK government and innovation funders (InnovateUK, NIHR, UCL CDI, KQ Labs, Adeline). The leadership team comprises four co-founders: CEO Nikolas Pontikos, PhD; CTO Ismail Moghul, PhD; Chief AI Officer William Woof, PhD; and CMO Professor Michel Michaelides.

Eye2Gene firmographics

Firmographics
Name
Eye2Gene
Legal name
Eye2Gene Ltd
Website
https://eye2gene.com
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
Eye2Gene is an AI-powered precision ophthalmology platform combining retinal imaging analysis with genomics to accelerate diagnosis of inherited retinal diseases for clinicians, pharmaceutical companies, and patients.
Ownership category
akta.pro rank

Eye2Gene industry classification

Industry
Product category
AI-Powered Precision Ophthalmology Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers

Keywords

  • AI ophthalmology platform
  • Retinal imaging analysis
  • Genomic decision support
  • Inherited retinal disease diagnosis
  • Clinical decision software

Where Eye2Gene is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Eye2Gene business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Platform subscription/usage: Eye2Gene provides its AI-powered clinical decision support platform to healthcare institutions, pharma companies, and researchers. The platform is described as clinical decision support software not yet approved for clinical use. Revenue likely derives from platform licensing, subscription agreements, or usage-based pricing for institutional access, though specific commercial terms are not publicly disclosed.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise platform access (quote-based)

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Eye2Gene product offering

Product offering

Core offering

Eye2Gene is an AI-powered precision ophthalmology platform that analyzes routine retinal imaging (OCT, FAF, IR) combined with genomic data to support clinicians in diagnosing inherited retinal diseases (IRDs). The platform generates ranked candidate gene lists and quantitative imaging biomarkers to streamline genetic testing workflows, accelerating diagnosis from years to weeks and supporting clinical trial patient identification for pharmaceutical partners.

Product overview

Eye2Gene is an AI-powered precision ophthalmology platform combining advanced imaging analysis with genomic insights. The core Eye2Gene Platform integrates AI-powered imaging analysis, genomics integration, genetic prioritisation, and quantitative biomarkers to accelerate inherited retinal disease diagnosis from years to weeks. The platform is supported by a Secure Data Portal enabling secure cloud infrastructure with encrypted data storage for research, clinical collaboration, and clinical trial readiness.

Differentiator

Problem solved

Functional benefit

Products and services

  • Eye2Gene Platform AI-powered clinical decision support platform that analyses routine retinal imaging (OCT, FAF, IR) combined with genomic sequencing data to assist clinicians, researchers, and pharmaceutical companies in diagnosing inherited retinal diseases (IRDs). Generates ranked candidate gene lists and quantitative imaging biomarkers to accelerate diagnosis from years to weeks and supports clinical trial patient identification.

Quantifiable outcome

  • Diagnosis timeline reduced from years to weeks
  • +2 more outcomes

Companies that use Eye2Gene

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Eye2Gene technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Eye2Gene partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, major and minor.

  • UCL Institute of OphthalmologycoreStrategic or Co-development PartnerFounding institution and primary research collaborator. Eye2Gene was created as a spinout from UCL. Ongoing collaboration on AI-powered inherited retinal disease diagnosis research, validation studies, and technology development.
  • Moorfields Eye Hospital NHS Foundation TrustcoreStrategic or Co-development PartnerLeading UK eye hospital and major clinical validation partner. Collaborating on clinical validation of Eye2Gene platform with genetically characterised IRD patient data. Key reference institution for clinical credibility.
  • University of OxfordcoreStrategic or Co-development PartnerClinical validation partner for Eye2Gene inherited retinal disease research. Collaborating on studies involving genetically characterised patients from Oxford.
  • University Hospital BonncoreStrategic or Co-development PartnerInternational clinical validation partner for Eye2Gene platform. Collaborating on inherited retinal disease studies with European patient populations.
  • Sight Research UKmajorStrategic or Co-development PartnerUK-based sight loss research charity. Collaborating on research into inherited retinal diseases and AI applications in ophthalmology.
  • Retina UKmajorStrategic or Co-development PartnerUK patient organisation for those affected by inherited retinal dystrophies. Collaborating on patient-focused research, webinars, and awareness activities.
  • Stargardt ConnectedminorStrategic or Co-development PartnerPatient advocacy group for Stargardt disease. Collaborating on patient engagement and community outreach.
  • Moorfields Eye CharitymajorStrategic or Co-development PartnerCharitable arm of Moorfields Eye Hospital supporting research and innovation in eye health. Supporting Eye2Gene research and development activities.
  • NHS Genomic AI NetworkmajorStrategic or Co-development PartnerNHS initiative supporting AI adoption in genomic medicine. Eye2Gene participates in NHS Clinical AI Interest Group activities for precision ophthalmology.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Eye2Gene competitors and assessment

Company assessment

Direct peers

  • Digital Diagnostics (IDx-DR): Digital Diagnostics pioneered autonomous AI diagnostic software in ophthalmology (IDx-DR). Comparable as a regulatory-grade AI diagnostics platform targeting ophthalmic clinical workflows.
  • RetinAI Medical: RetinAI builds AI tools (Discovery, iPredict) for OCT and fundus image analysis to support diagnosis and clinical trial recruitment in retinal disease. Directly comparable to Eye2Gene's imaging-based decision support and pharma patient-stratification focus.
  • Eyenuk: Eyenuk develops FDA-cleared AI for retinal imaging (EyeArt for diabetic retinopathy). It is a direct peer to Eye2Gene in AI-based retinal disease detection, though focused on DR rather than IRDs.

Emerging players

  • Voxeleron: Voxeleron provides OCT image analysis software and biomarkers for ophthalmic clinical research. Relevant peer in retinal image quantification that complements the imaging-analysis half of Eye2Gene's platform.
  • AEYE Health: AEYE Health develops AI screening for diabetic retinopathy from retinal images, focused on primary care. Emerges as a peer in retinal AI diagnostics, overlapping with Eye2Gene's imaging-based triage/decision support value prop.

Others

  • Tempus AI: Tempus builds multimodal AI combining imaging, genomic, and clinical data to inform precision medicine, including in ophthalmology. Adjacent enabling peer representing the broader precision-medicine AI infrastructure Eye2Gene's imaging-genomics model resembles.
  • Genomics England / NHS Genomic Medicine Service: UK national genomics initiatives in inherited disease diagnosis. Adjacent ecosystem participant and potential buyer/partner for Eye2Gene's genetic prioritisation technology in the NHS pathway.

Broad incumbents

  • Google Health (DeepMind Retina): DeepMind (Google Health) has published foundational AI work on OCT-based retinal disease detection. Broad incumbent peer representing the big-tech competitive threat in AI retinal diagnostics.
  • Heidelberg Engineering: Heidelberg Engineering develops SPECTRALIS OCT and fundus imaging platforms widely used in retinal care. An incumbent imaging-device vendor whose hardware Eye2Gene's software analyses, and which itself markets image-analysis software for retinal disease.
  • Carl Zeiss Meditec: Carl Zeiss Meditec is a major ophthalmology device vendor (Cirrus OCT, Humphrey field analyser) with growing clinical software offerings. Broad incumbent comparable as the wider ophthalmology imaging/diagnostics ecosystem Eye2Gene operates in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Eye2Gene social profiles

Digital presence

Eye2Gene compliance and trust

Trust signal

Compliance7 records

Eye2Gene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eye2Gene leadership team

Management profile

Number of profiles

Profiles5 records

Eye2Gene funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eye2Gene M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eye2Gene

What does Eye2Gene do?

Eye2Gene is an AI-powered precision ophthalmology platform that analyzes routine retinal imaging (OCT, FAF, IR) combined with genomic data to support clinicians in diagnosing inherited retinal diseases (IRDs). The platform generates ranked candidate gene lists and quantitative imaging biomarkers to streamline genetic testing workflows, accelerating diagnosis from years to weeks and supporting clinical trial patient identification for pharmaceutical partners.

Is Eye2Gene a public or private company?

Eye2Gene is a private company. It is classified as venture growth investor backed and is currently operating.

When was Eye2Gene founded?

Eye2Gene was founded in -1. It employs 11 to 50 people.

Where is Eye2Gene based?

Eye2Gene is headquartered in London, United Kingdom, in the Europe region.

How does Eye2Gene make money?

One revenue line is on record: platform subscription/usage.

Who are Eye2Gene's main competitors?

Direct peers on record are Digital Diagnostics (IDx-DR), RetinAI Medical and Eyenuk. Emerging players are Voxeleron and AEYE Health. Others are Tempus AI and Genomics England / NHS Genomic Medicine Service. Broad incumbents are Google Health (DeepMind Retina), Heidelberg Engineering and Carl Zeiss Meditec.

Does Eye2Gene have an API?

No public API is recorded for Eye2Gene.

What industry is Eye2Gene in?

Eye2Gene's product category is AI-Powered Precision Ophthalmology Software. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography), with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals